HDL2 interferes with LDL association with arterial proteoglycans: a possible athero-protective effect

Atherosclerosis. 2012 Nov;225(1):115-20. doi: 10.1016/j.atherosclerosis.2012.08.040. Epub 2012 Sep 13.

Abstract

Objectives: High levels of large HDL (HDL2) reduce cardiovascular disease risks apparently because it mediates reverse cholesterol transport, and it has anti-inflammatory properties. Here we explored the mechanism behind an additional athero-protective HDL effect related to its capacity to interfere with formation of insoluble LDL-proteoglycans associations, a key step in LDL entrapment in the intima and in atherogenesis.

Methods and results: We found that HDL2 levels from type 2 diabetes patients and controls are inversely correlated with complex formation between serum LDL and the arterial proteoglycans versican. Reconstitution experiments indicate that HDL2 was more efficacious inhibitor of the LDL-versican association than the smaller HDL3. This may explain why serum from patients with dyslipidemia of insulin resistance, with low levels of HDL2, have a higher capacity to form insoluble LDL-proteoglycan complex. ApoE enrichment of HDL2 and HDL3 or addition of copies of an apoE peptide with the proteoglycan-binding sequence of this apolipoprotein increased their inhibition of LDL-versican associations.

Conclusions: The inhibitory effect of HDL2 and HDL3 on LDL-versican associations was related to formation of apoE-mediated soluble HDL-versican complexes. We speculate that in the intima large, HDL2 subclasses, by forming reversible soluble associations with proteoglycans can compete with formation of irreversible LDL-proteoglycan aggregates. This can contribute to the HDL2 athero-protective effects. In the dyslipidemia of insulin resistance, associated with low levels of HDL2, this athero-protective property may be compromised.

MeSH terms

  • Apolipoproteins E / metabolism
  • Atherosclerosis / prevention & control*
  • Diabetes Mellitus, Type 2
  • Humans
  • Insulin Resistance / physiology
  • Lipoproteins, HDL2 / pharmacology*
  • Lipoproteins, HDL3 / pharmacology
  • Lipoproteins, LDL / metabolism*
  • Male
  • Versicans / metabolism*

Substances

  • Apolipoproteins E
  • Lipoproteins, HDL2
  • Lipoproteins, HDL3
  • Lipoproteins, LDL
  • VCAN protein, human
  • Versicans